<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Biochem Nutr</journal-id><journal-id journal-id-type="publisher-id">JCBN</journal-id><journal-title-group><journal-title>Journal of Clinical Biochemistry and Nutrition</journal-title></journal-title-group><issn pub-type="ppub">0912-0009</issn><issn pub-type="epub">1880-5086</issn><publisher><publisher-name>the Society for Free Radical Research Japan</publisher-name><publisher-loc>Kyoto, Japan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26388672</article-id><article-id pub-id-type="pmc">4566023</article-id><article-id pub-id-type="publisher-id">jcbn14-132</article-id><article-id pub-id-type="doi">10.3164/jcbn.14-132</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of nutritional counseling and long term isomaltulose based liquid formula (MHN-01) intake on metabolic syndrome</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Takeda</surname><given-names>Eiji</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Yamanaka-Okumura</surname><given-names>Hisami</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Taketani</surname><given-names>Yutaka</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Inagaki</surname><given-names>Nobuya</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hosokawa</surname><given-names>Masaya</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shide</surname><given-names>Kenichiro</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Maegawa</surname><given-names>Hiroshi</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kondo</surname><given-names>Keiko</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Kawasaki</surname><given-names>Eiji</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Shinozaki</surname><given-names>Shoko</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Fujinaka</surname><given-names>Yuichi</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Matsubara</surname><given-names>Tsukasa</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Katayama</surname><given-names>Takafumi</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Sasaki</surname><given-names>Hajime</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="author-notes" rid="fn1">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Kawashima</surname><given-names>Akihiro</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Aonuma</surname><given-names>Hiromitsu</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Clinical Nutrition, Institute of Health Biosciences, University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan</aff><aff id="aff2"><label>2</label>Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan</aff><aff id="aff3"><label>3</label>Department of Clinical Nutrition, School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan</aff><aff id="aff4"><label>4</label>Division of Endocrinology and Metabolism, Department of Medicine, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Shiga 520-2192, Japan</aff><aff id="aff5"><label>5</label>Department of Metabolism/Diabetes and Clinical Nutrition, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan</aff><aff id="aff6"><label>6</label>Division of Dietary Service, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan</aff><aff id="aff7"><label>7</label>Endocrinology and Metabolism, Tokushima University Medical and Dental Hospital, 2-50-1 Kuramoto-cho, Tokushima 770-8503, Japan</aff><aff id="aff8"><label>8</label>Director, Matsubara Mayflower Hospital, 944-55 Fujita, Kato, Hyogo 673-1462, Japan</aff><aff id="aff9"><label>9</label>Faculty of Statistic and Computer Science, College of Nursing Art and Science, University of Hyogo, 13-71 Kitaoji-cho, Akashi, Hyogo 673-8588, Japan</aff><aff id="aff10"><label>10</label>Food Science Research Labs., R&#x00026;D Div., Meiji Co., Ltd., 540 Narita, Odawara, Kanagawa 250-0862, Japan</aff><author-notes><corresp id="cor1">*To whom correspondence should be addressed. E-mail: <email>takeda.eiji@tokushima-u.ac.jp</email></corresp><fn id="fn1"><label>&#x02020;</label><p>Present address: Department of Nutrition and Life Sciences, Kanagawa Institute of Technology, 1030 Shimo-ogino, Atsugi, Kanagawa 243-0292, Japan</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>6</day><month>8</month><year>2015</year></pub-date><volume>57</volume><issue>2</issue><fpage>140</fpage><lpage>144</lpage><history><date date-type="received"><day>21</day><month>10</month><year>2014</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 JCBN</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>The isomaltulose based liquid formula (MHN-01), suppresses postprandial plasma glucose and insulin levels in healthy persons and patients with impaired glucose tolerance (IGT) or type 2 diabetes. MHN-01 intake as a part of breakfast also suppresses glucose and insulin levels after lunch, suggesting second meal effect. The objective of this study was to investigate the effects of nutritional counseling and long-term (24 weeks) MHN-01 ingestion on biomarkers of metabolic syndrome. Forty-one subjects with criteria of metabolic syndrome participated in this study composed with the control period (0&#x02013;12 week) followed by nutritional counseling and the experimental period (12&#x02013;36 week) followed by 200&#x000a0;kcal (837&#x000a0;kJ) of MHN-01 or dextrin-based standard balanced liquid formula (SBF) loading as a part of breakfast. In 16 of 41 subjects became to out of criteria for liquid formula loading study during control period (unqualified group). In the unqualified group, several biomarkers were improved. In experimental period, serum HbA<sub>1c</sub> levels significantly increased in SBF group (<italic>n</italic>&#x000a0;=&#x000a0;12) but did not change in MHN-01 group (<italic>n</italic>&#x000a0;=&#x000a0;10). Thus, intake of 837&#x000a0;kJ MHN-01 as a part of breakfast may be effective for suppression of deteriorating glucose metabolism in metabolic syndrome.</p></abstract><kwd-group><kwd>postprandial hyperglycemia</kwd><kwd>insulin</kwd><kwd>diabetes</kwd><kwd>impaired glucose tolerance</kwd></kwd-group></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><p>Abdominal obesity is frequently associated with a collection of metabolic disorders that include elevated blood pressure, characteristic lipid abnormalities (low high-density lipoprotein cholesterol and high triglycerides) and increased fasting glucose, with an underlying situation of insulin resistance, which has been defined as metabolic syndrome, conferring a high cardiovascular risk profile to these subjects. A multidisciplinary approach, including lifestyle changes and pharmacological and surgical approaches is required for prevention and treatment of metabolic syndrome.</p><p>Anti-hyperglycemic therapy focused on control of postprandial glucose level has a greater impact on overall metabolic control, and thus improves long-term outcome compared with the more traditional approaches focused on fasting glucose level.<sup>(<xref rid="B1" ref-type="bibr">1</xref>)</sup> Cohort studies have shown that postprandial hyperglycemia is an independent risk factor for cardiovascular disease.<sup>(<xref rid="B2" ref-type="bibr">2</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>)</sup> In the STOP-NIDDM study, correction of postprandial hyperglycemia reduced the onset of myocardial infarction.<sup>(<xref rid="B5" ref-type="bibr">5</xref>)</sup> Dietary carbohydrates influence insulin secretion, postprandial plasma glucose, and plasma lipid profile.<sup>(<xref rid="B6" ref-type="bibr">6</xref>)</sup> The glycemic index (GI) was proposed as a system for classifying carbohydrate-containing foods according to glycemic response.<sup>(<xref rid="B7" ref-type="bibr">7</xref>)</sup> Another point concerning the deterioration of the glycemic profiles is the significant increase in glucose levels during the morning periods in type 2 diabetic patients due to an overproduction of glucose by the liver.<sup>(<xref rid="B8" ref-type="bibr">8</xref>)</sup> These metabolic disturbances known as &#x0201c;dawn phenomenon&#x0201d;<sup>(<xref rid="B9" ref-type="bibr">9</xref>)</sup> is observed at prebreakfast time, but have a prolonged deleterious effect on glucose levels over the entire postbreakfast period.</p><p>Ingestion of isomaltulose by type 2 diabetic humans and rats resulted in a reduction in their postprandial plasma glucose and insulin levels.<sup>(<xref rid="B10" ref-type="bibr">10</xref>,<xref rid="B11" ref-type="bibr">11</xref>)</sup> In our previous studies, the isomaltulose based liquid formula (MHN-01) containing isomaltulose and oleic acid suppresses postprandial hyperglycemia and hyperinsulinemia in humans and Sprague-Dawley rats, reduces visceral fat accumulation, and improves insulin sensitivity in Sprague-Dawley rats.<sup>(<xref rid="B12" ref-type="bibr">12</xref>&#x02013;<xref rid="B14" ref-type="bibr">14</xref>)</sup> Consumption of MHN-01 at breakfast also appeared to improve glycemic control by reducing postprandial plasma glucose and insulin levels after lunch (second meal effect) in healthy men.<sup>(<xref rid="B13" ref-type="bibr">13</xref>)</sup> However, it is not clear that the effect of continuous MHN-01 intake at breakfast improves glucose metabolism in metabolic syndrome. This prospective, multicenter, blind and randomized control study was designed to investigate the effects of long-term MHN-01 ingestion as a part of breakfast on glycemic control and body composition in metabolic syndrome.</p></sec><sec sec-type="materials|methods"><title>Materials and Methods</title><sec><title>Subjects</title><p>Individuals were eligible to participate if they met the following inclusion criteria. In the control and the experimental periods of this study, they had more than 25&#x000a0;kg/m<sup>2</sup> of body mass index (BMI), 100&#x02013;125&#x000a0;mg/dl of fasting plasma glucose (FPG), 5.2&#x02013;6.5% of hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) and were between the ages of 20 and 70 years. This study was carried out at 5 hospitals (Kyoto University Hospital, Shiga University Hospital, Nagasaki University Hospital, Tokushima University Hospital and Matsubara Mayflower Hospital) and ethical approval was received from each hospital. Patients with diabetes treated with drugs, with pancreatic diseases, with endocrine diseases such as Cushing&#x02019;s syndrome and thyroid diseases, hepatic diseases, gastric diseases, heavy alcohol drinkers, pregnant and lactating women were excluded from this study. Between February 2008 and December 2010, 41 residents who met the study entry criteria of metabolic syndrome were enrolled in this study.</p></sec><sec><title>Study design</title><p>The study was divided by the control period in that subjects obtained nutritional counseling for 12 weeks (0&#x02013;12 week) by registered dietitians and 24 week experimental period (12&#x02013;36 week) followed by 200&#x000a0;kcal (837&#x000a0;kJ) of MHN-01 or dextrin-based standard balanced liquid formula (SBF) loading as a part of breakfast that was a prospective, randomized, open, blinded-endpoint design and multiple center trial (Fig.&#x000a0;<xref ref-type="fig" rid="F1">1</xref>).</p><p>In the control period, each subject was consulted on energy intake with 30&#x000a0;kcal/kg of ideal body weight/day every month by registered dietitians. Energy intake and dietary habits in each subject were calculated from daily dietary records. A dietician calculated the quantity of intake energy from each patient&#x02019;s dietary records and the mean values for the 3 days leading up to the scheduled clinic visits were determined. The total energy of the breakfast in the experimental period was fixed to that of the control period based on each dietary record. The subjects were asked to maintain a constant lifestyle and kept a dietary record to be completed during the 3 days prior to each scheduled visit to each of the institutions.</p><p>In the experimental period, eligible subjects were randomized to receive low glycemic index (GI) MHN-01 and SBF. The subjects visited at 0, 4, 8, 12, 24 and 36 week for collection of body composition measurement, and provided 3-day&#x02019;s dietary records. Fasting blood samples were taken by venipuncture on 0, 12, 24, 36 week for analysis of parameters of carbohydrate and lipid metabolism. Abdominal fat value was assessed by CT scan on 12 and 36 weeks.</p><p>The study was performed after obtaining written informed consent from all patients, and was approved by the Ethics Committee of each institution. The protocol conformed to the Helsinki Declaration. The aim and study design were registered to Umin (Unique ID issued by UMIN: UMIN000001301) before the start of this study.</p></sec><sec><title>Liquid formulas</title><p>MHN-01 was prepared by partially replacing dextrin in SBF with 55.7% isomaltulose of carbohydrate and 72.3% of oleic acid of fat. The protein, fat, and carbohydrate % of energy were 20.0%, 29.7%, and 50.3%, respectively. SBF was a dextrin-formula that also contained sucrose; the protein, fat, and carbohydrate % of energy were 16.0%, 25.0%, and 59.0%, respectively (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>).</p></sec><sec><title>Methods for analysis</title><p>Plasma samples were kept at &#x02212;20&#x000b0;C until analyzed. Plasma glucose concentration was measured by using a glucose oxidase-based autoanalyzer. Serum insulin concentration was measured by a standard radioimmunoassay. The total incremental area under the curve (AUC) for plasma glucose and insulin were calculated for a 180-min period after ingestion of each liquid formula. The insulin resistance index was calculated using the homeostasis model assessment for insulin resistance (HOMA-IR&#x000a0;=&#x000a0;fasting insulin (&#x000b5;U/ml)&#x000a0;&#x000d7;&#x000a0;fasting glucose (mmol/L)&#x000a0;/ 22.5). HbA<sub>1c</sub> concentration was determined by high-performance liquid chromatography; serum triglyceride, total cholesterol, and high density lipoprotein (HDL) cholesterol concentrations were determined by enzymatic techniques using a Hitachi Model 736 auto-analyzer (Mito, Japan). Serum adiponectin concentrations were measured by human adiponectin ELISA kit (Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan).</p></sec><sec><title>Statistical analyses</title><p>Data are presented as mean&#x000a0;&#x000b1;&#x000a0;SD. Changes chemical and clinical parameters were analyzed using Wilcoxon matched-pairs signed-rank test. In addition, to adjust for age and BMI, multiple linear regression analysis was used. Significance was determined at &#x0003c;0.05. All statistical analyses were performed with Stat View for Windows, ver. 5.0 (SAS Institute; Cary, NC).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Changes of clinical parameters by nutritional counseling</title><p>The clinical characteristics of entry subjects and change of the anthropometric and laboratory data from the beginning to the end of the control period (0&#x02013;12 week) are shown in Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>. Daily total energy intake, blood pressure and serum HbA<sub>1c</sub> level significantly decreased and fasting immunoreactive insulin (FIRI) and HOMA-IR levels significantly increased during the control period possibly due to the nutritional counseling and subsequent dietary changes. No significant changes were observed in body weight, BMI, waist circumference or fasting plasma glucose level and any other parameters in this period.</p></sec><sec><title>Comparison of clinical parameters changed in two groups with or without improvement during the control period</title><p>Sixteen of 41 subjects could not proceed to long term liquid formula administration study because of becoming to be out of criteria. In that unqualified group, several biomarkers were improved. In the unqualified (improved) group (<italic>n</italic>&#x000a0;=&#x000a0;16) during 12 weeks, daily total energy intake, HbA<sub>1c</sub> and blood pressure significantly decreased (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). In qualified (non-improved) group (<italic>n</italic>&#x000a0;=&#x000a0;25), diastolic blood pressure and HbA<sub>1c</sub> levels decreased and both FIRI and HOMA-IR levels increased for 12 weeks. Daily total energy intake in unqualified (improved) group was significantly higher than those in qualified (non-improved) group at 0 week of this study. HbA<sub>1c</sub> levels in unqualified (improved) group were also lower than those in qualified (non-improved) group at 0 week and 12 week.</p></sec><sec><title>Effect of MHN-01 intake on clinical parameters</title><p> During the experimental period, 25 subjects residing in two long-term care facilities were enrolled in the study, and two subjects withdrew due to conflicts of schedule and health problems unrelated to the study, and one subject was excluded from analysis due to poor compliance. Therefore, all long-term study data were analyzed and are presented 10 subjects in MHN-01 group and 12 in SBF group completed the entire 24-week study. Serious side effects such as anemia, renal, or hepatic disorders did not appear during this study.</p><p>In the group ingested 200&#x000a0;kcal (837&#x000a0;kJ) MHN-01 as a part of breakfast during the experimental period, no significant changes were observed in body weight, BMI, abdominal visceral fat, fasting plasma glucose, fasting insulin, triacylglycerol, total cholesterol, or HDL cholesterol levels or AUC for glucose and insulin. In contrast, in control group ingested 200&#x000a0;kcal (837&#x000a0;kJ) SBF, HbA<sub>1c</sub> levels were significantly increased at 36 week comparing with those at 12 weeks (Table&#x000a0;<xref ref-type="table" rid="T4">4</xref>). Furthermore, the incremental change of HbA<sub>1c</sub> level from 12 week to 36 week in SBF group was significantly higher than those in MHN-01 group. Thus, increase of HbA<sub>1c</sub> levels was suppressed by MHN-01 ingestion.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>The lifestyle modifications that combine energy restriction and healthy eating (increased intake of fruits, vegetables, fish and water and reduced consumption of sugar, fat, sodium, and fried foods) would appear to be a preferred treatment strategy for metabolic syndrome. In this study, 16 of 41 subjects became to be out of criteria by nutritional counseling for 12 weeks. Improved group was characterized by higher energy intake and lower serum HbA<sub>1c</sub> level at 0 week, suggesting poor lifestyle and short period of glucose metabolic impairment. Several studies have revealed the importance of nutritional education aiming at preventing metabolic syndrome.<sup>(<xref rid="B15" ref-type="bibr">15</xref>&#x02013;<xref rid="B17" ref-type="bibr">17</xref>)</sup> The present study confirmed this by observing a significant decline in energy intake and HbA<sub>1c</sub> in the improved group.</p><p>Glycated hemoglobin (HbA<sub>1c</sub>) levels are closely associated with postprandial glucose levels in type 2 diabetes, in comparison with fasting glucose levels.<sup>(<xref rid="B18" ref-type="bibr">18</xref>)</sup> Since energy amounts during the experimental period were unchanged, it is conceivable that the maintaining serum HbA<sub>1c</sub> levels in MHN-01 group rather than increased concentration in SBF group is due to the effect of the long-term (24 weeks) ingestion of MHN-01 as a part of breakfast in these subjects with metabolic syndrome. The glycemic index of foods is now considered to be an important feature in the development of insulin resistance as determined by HOMA-IR. After adjustment for potential confounding variables, total but also fruit and cereal dietary fiber intakes were inversely associated with HOMA-IR in the Framingham Offspring Study.<sup>(<xref rid="B19" ref-type="bibr">19</xref>)</sup></p><p>A previous study demonstrated that peak plasma glucose and IRI levels at 30&#x000a0;min after MHN-01 loading were lower than after SBF loading in the human study.<sup>(<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>)</sup> Postprandial fat oxidation rates in the MHN-01 group were higher than those in the SBF group. The free fatty acid (FFA) concentration in the MHN-01 group immediately before lunch was significantly lower than that in the SBF group. Plasma glucose and IRI levels in the MHN-01 group after the standard lunch were lower than those in the SBF group, though the peak levels in these groups were not different. Development of type 2 diabetes is associated with progressive histopathological changes in pancreatic islets, including selective loss of &#x003b2;-cells and fibrosis.<sup>(<xref rid="B20" ref-type="bibr">20</xref>)</sup> The most obvious mechanism to explain pancreatic decompensation is a progressive loss of &#x003b2;-cell mass, which is hastened by islet fibrosis. Our data demonstrated that isomaltulose, relative to sucrose, had an antifibrotic effect on the islets of Zucker fatty rats.<sup>(<xref rid="B21" ref-type="bibr">21</xref>)</sup> Sucrose-fed rats showed a much higher proportion of distinctly fibrotic islets than isomaltulose-fed rats. Furthermore, a recent systematic review of short-term randomized feeding trials in diabetic patients showed that low-GI diets were associated with improvements of glycemic control, insulin sensitivity, and other intermediate biomarkers.<sup>(<xref rid="B22" ref-type="bibr">22</xref>)</sup> There is also an indication that lean, physically active subjects can adjust to the postprandial glucose challenge following a high-GI meal by increasing insulin sensitivity, while obese, inactive subjects must increase their insulin secretion in order to reestablish glucose homeostasis.<sup>(<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>)</sup></p><p>In a recent study in healthy subjects, &#x003b2;-cell function and insulin sensitivity progressively improved in the postprandial state as the proportion of mono-unsaturated fatty acids (MUFAs) with respect to saturated fatty acids (SFAs) in fatty meals increased.<sup>(<xref rid="B25" ref-type="bibr">25</xref>)</sup> Also, in a cross-sectional study of the general population in the Southeast of Spain, an oral glucose tolerance test was used in 538 subjects to calculate insulin resistance and &#x003b2;-cell function derived from HOMA indexes and results showed a favorable association between MUFA intake and insulin secretion.<sup>(<xref rid="B26" ref-type="bibr">26</xref>)</sup> Recent data from subjects of a Mediterranean country with high dietary MUFA intake in the form of olive oil show a significant inverse association between the serum phospholipid proportions of oleic acid, the main MUFA, and insulin resistance assessed by the HOMA method.<sup>(<xref rid="B27" ref-type="bibr">27</xref>)</sup> Findings from obese Zucker rats fed for 4 vs 8 weeks provide strong evidence that pancreatic islets may be target sites that translate the effects of different combinations of dietary carbohydrates and fats into metabolic changes.<sup>(<xref rid="B28" ref-type="bibr">28</xref>)</sup></p><p>Development of type 2 diabetes is associated with progressive histopathological changes in pancreatic islets, including selective loss of &#x003b2;-cells and fibrosis.<sup>(<xref rid="B28" ref-type="bibr">28</xref>)</sup> The most obvious mechanism to explain pancreatic decompensation is a progressive loss of &#x003b2;-cell mass, which is hastened by islet fibrosis. Therefore, our previous findings indicate that sucrose and linoleic acid together may act to induce subtle but striking changes in pancreatic islets long before manifestation of type 2 diabetes symptoms. A combination of isomaltulose and oleic acid, which would help preserve of &#x003b2;-cells and prevent deleterious changes in pancreatic islets, may reduce the risk of developing obesity, type 2 diabetes and metabolic syndrome.</p><p>Regarding the absence of disease or infirmity there is excellent evidence that low-GI diets reduce the risk for many diseases.<sup>(<xref rid="B29" ref-type="bibr">29</xref>)</sup> All this suggests that GI influences physiological functions in ways that are relevant to virtually everyone. This is particularly important for Asian because the glycemic response to the foods was higher in Asian Indian subjects compared with UK Caucasian subjects, although there were no significant differences in the GI values of the same foods between the two groups.<sup>(<xref rid="B29" ref-type="bibr">29</xref>)</sup> Because this study was carried out with a small number of subjects, further study with larger populations should be initiated to support our findings. In conclusion, we suggest that long-term ingestion of MHN-01 as a part of breakfast may be effective in keeping patients with metabolic syndrome under good glucose and lipid metabolism.</p></sec></body><back><ack><title>Acknowledgments</title><p>This study was carried out by total support by Meiji Co., Ltd.</p></ack><sec><title>Conflict of Interest</title><p>H.S., A.K., and H.A. are employees of Meiji Co., Ltd.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bastyr</surname><given-names>EJ</given-names><suffix>3rd</suffix></name><name><surname>Stuart</surname><given-names>CA</given-names></name><name><surname>Brodows</surname><given-names>RG</given-names></name><etal/></person-group><article-title>Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA<sub>1c</sub>. IOEZ Study Group</article-title><source>Diabetes Care</source><year>2000</year><volume>23</volume><fpage>1236</fpage><lpage>1241</lpage><pub-id pub-id-type="pmid">10977012</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><collab>DECODE Study Group, the European Diabetes Epidemiology Group</collab><article-title>Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria</article-title><source>Arch Intern Med</source><year>2001</year><volume>161</volume><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">11176766</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagami</surname><given-names>T</given-names></name></person-group><collab>DECODA Study Group</collab><article-title>Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin</article-title><source>Diabetologia</source><year>2004</year><volume>47</volume><fpage>385</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">14985967</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tominaga</surname><given-names>M</given-names></name><name><surname>Eguchi</surname><given-names>H</given-names></name><name><surname>Manaka</surname><given-names>H</given-names></name><name><surname>Igarashi</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Sekikawa</surname><given-names>A</given-names></name></person-group><article-title>Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study</article-title><source>Diabetes Care</source><year>1999</year><volume>22</volume><fpage>920</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">10372242</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiasson</surname><given-names>JL</given-names></name><name><surname>Josse</surname><given-names>RG</given-names></name><name><surname>Gomis</surname><given-names>R</given-names></name><name><surname>Hanefeld</surname><given-names>M</given-names></name><name><surname>Karashik</surname><given-names>A</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name></person-group><collab>STOP-NIDDM Trial Research Group</collab><article-title>Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>486</fpage><lpage>494</lpage><pub-id pub-id-type="pmid">12876091</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludwig</surname><given-names>DS</given-names></name></person-group><article-title>The glycemic index: physiological mechanisms relating to obesity, diabetes and cardiovascular disease</article-title><source>JAMA</source><year>2002</year><volume>287</volume><fpage>2414</fpage><lpage>2423</lpage><pub-id pub-id-type="pmid">11988062</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>DJ</given-names></name><name><surname>Wolever</surname><given-names>TM</given-names></name><name><surname>Taylor</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Glycemic index of foods: a physiological basis for carbohydrate exchange</article-title><source>Am J Clin Nutr</source><year>1981</year><volume>34</volume><fpage>362</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">6259925</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Urbain</surname><given-names>JL</given-names></name></person-group><article-title>Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production</article-title><source>Diabetes</source><year>1996</year><volume>45</volume><fpage>1044</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">8690150</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolli</surname><given-names>GB</given-names></name><name><surname>Gerich</surname><given-names>JE</given-names></name></person-group><article-title>The &#x0201c;dawn phenomenon&#x0201d;--a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus</article-title><source>N Engl J Med</source><year>1984</year><volume>310</volume><fpage>746</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">6366551</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuda</surname><given-names>Y</given-names></name><name><surname>Kawai</surname><given-names>K</given-names></name><name><surname>Chiba</surname><given-names>Y</given-names></name><name><surname>Koide</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name></person-group><article-title>Effects of parenteral palatinose on glucose metabolism in normal and streptozotocin diabetic rats</article-title><source>Horm Metab Res</source><year>1986</year><volume>18</volume><fpage>361</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">3525361</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>K</given-names></name><name><surname>Yoshikawa</surname><given-names>H</given-names></name><name><surname>Murayama</surname><given-names>Y</given-names></name><name><surname>Okuda</surname><given-names>Y</given-names></name><name><surname>Yamashita</surname><given-names>K</given-names></name></person-group><article-title>Usefulness of palatinose as a caloric sweetener for diabetic patients</article-title><source>Horm Metab Res</source><year>1989</year><volume>21</volume><fpage>338</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">2673967</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>A</given-names></name><name><surname>Matsuo</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effect of a novel palatinose-based liquid balanced formula (MHN-01) on glucose and lipid metabolism in male Sprague-Dawley rats after short- and long-term ingestion</article-title><source>Metabolism</source><year>2004</year><volume>53</volume><fpage>977</fpage><lpage>983</lpage><pub-id pub-id-type="pmid">15281004</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>A</given-names></name><name><surname>Sakuma</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effects of a palatinose-based liquid diet (Inslow) on glycemic control and the second-meal effect in healthy men</article-title><source>Metabolism</source><year>2007</year><volume>56</volume><fpage>115</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">17161233</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakuma</surname><given-names>M</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>A</given-names></name><etal/></person-group><article-title>Improvement of glucose metabolism in patients with impaired glucose tolerance or diabetes by long-term administration of a palatinose-based liquid formula as a part of breakfast</article-title><source>J Clin Biochem Nutr</source><year>2009</year><volume>45</volume><fpage>155</fpage><lpage>162</lpage><pub-id pub-id-type="pmid">19794923</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruner</surname><given-names>B</given-names></name><name><surname>Chad</surname><given-names>K</given-names></name><name><surname>Chizen</surname><given-names>D</given-names></name></person-group><article-title>Effects of exercise and nutritional counseling in women with polycystic ovary syndrome</article-title><source>Appl Physiol Nutr Metab</source><year>2006</year><volume>31</volume><fpage>384</fpage><lpage>391</lpage><pub-id pub-id-type="pmid">16900227</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>T</given-names></name><name><surname>Avenell</surname><given-names>A</given-names></name><name><surname>Edmunds</surname><given-names>LD</given-names></name><etal/></person-group><article-title>Systematic review of long-term lifestyle interventions to prevent weight gain and morbidity in adults</article-title><source>Obes Rev</source><year>2009</year><volume>10</volume><fpage>627</fpage><lpage>638</lpage><pub-id pub-id-type="pmid">19754634</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>RR</given-names></name><name><surname>Zhao</surname><given-names>JP</given-names></name><name><surname>Jin</surname><given-names>H</given-names></name><etal/></person-group><article-title>Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain</article-title><source>JAMA</source><year>2008</year><volume>299</volume><fpage>185</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">18182600</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avignon</surname><given-names>A</given-names></name><name><surname>Radauceanu</surname><given-names>A</given-names></name><name><surname>Monnier</surname><given-names>L</given-names></name></person-group><article-title>Nonfasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes</article-title><source>Diabetes Care</source><year>1997</year><volume>20</volume><fpage>1822</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">9405900</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeown</surname><given-names>NM</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Saitzman</surname><given-names>E</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Jacques</surname><given-names>PF</given-names></name></person-group><article-title> Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>538</fpage><lpage>546</lpage><pub-id pub-id-type="pmid">14747241</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tikellis</surname><given-names>C</given-names></name><name><surname>Wookey</surname><given-names>PJ</given-names></name><name><surname>Candido</surname><given-names>R</given-names></name><name><surname>Andrikopoulos</surname><given-names>S</given-names></name><name><surname>Thomas</surname><given-names>MC</given-names></name><name><surname>Cooper</surname><given-names>ME</given-names></name></person-group><article-title>Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>989</fpage><lpage>997</lpage><pub-id pub-id-type="pmid">15047614</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>A</given-names></name><etal/></person-group><article-title>Dietary palatinose and oleic acid ameliorate disorders of glucose and lipid metabolism in Zucker fatty rats</article-title><source>J Nutr</source><year>2007</year><volume>137</volume><fpage>1908</fpage><lpage>1915</lpage><pub-id pub-id-type="pmid">17634263</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>D</given-names></name><name><surname>Elliott</surname><given-names>EJ</given-names></name></person-group><article-title>Low glycaemic index, or low glycaemic load, diets for diabetes mellitus</article-title><source>Cochrane Database Syst Rev</source><year>2009</year><volume>1</volume><fpage>CD006296</fpage><pub-id pub-id-type="pmid">19160276</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunehag</surname><given-names>AL</given-names></name><name><surname>Toffolo</surname><given-names>G</given-names></name><name><surname>Treuth</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Effects of dietary macronutrient content on glucose metabolism in children</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>5168</fpage><lpage>5178</lpage><pub-id pub-id-type="pmid">12414888</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>TPJ</given-names></name><name><surname>Haus</surname><given-names>JM</given-names></name><name><surname>Kelly</surname><given-names>KR</given-names></name><etal/></person-group><article-title>Randomized trial on the effects of a 7-d low-glycemic diet and exercise intervention on insulin resistance in older obese humans</article-title><source>Am J Clin Nutr</source><year>2009</year><volume>90</volume><fpage>1222</fpage><lpage>1229</lpage><pub-id pub-id-type="pmid">19793849</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez</surname><given-names>S</given-names></name><name><surname>Berm&#x000fa;dez</surname><given-names>B</given-names></name><name><surname>Pacheco</surname><given-names>YM</given-names></name><name><surname>Villar</surname><given-names>J</given-names></name><name><surname>Abia</surname><given-names>R</given-names></name><name><surname>Muriana</surname><given-names>FJ</given-names></name></person-group><article-title> Distinctive postprandial modulation of beta cell function and insulin sensitivity by dietary fats: monounsaturated compared with saturated fatty acids</article-title><source>Am J Clin Nutr</source><year>2008</year><volume>88</volume><fpage>638</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">18779278</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rojo-Mart&#x000ed;nez</surname><given-names>G</given-names></name><name><surname>Esteva</surname><given-names>I</given-names></name><name><surname>Ruiz de Adana</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Dietary fatty acids and insulin secretion: a population-based study</article-title><source>Eur J Clin Nutr</source><year>2006</year><volume>60</volume><fpage>1195</fpage><lpage>1200</lpage><pub-id pub-id-type="pmid">16639414</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sala-Vila</surname><given-names>A</given-names></name><name><surname>Cof&#x000e1;n</surname><given-names>M</given-names></name><name><surname>Mateo-Gallego</surname><given-names>R</given-names></name><etal/></person-group><article-title>Inverse association between serum phospholipid oleic acid and insulin resistance in subjects with primary dyslipidaemia</article-title><source>Clin Nutr</source><year>2011</year><volume>30</volume><fpage>590</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">21458117</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Miyazawa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Palatinose and oleic acid act together to prevent pancreatic islet disruption in nondiabetic obese Zucker rats</article-title><source>J Med Invest</source><year>2008</year><volume>55</volume><fpage>183</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">18797130</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salas-Salvad&#x000f3;</surname><given-names>J</given-names></name><name><surname>Martinez-Gonz&#x000e1;lez</surname><given-names>M&#x000c1;</given-names></name><name><surname>Bull&#x000f3;</surname><given-names>M</given-names></name><name><surname>Ros</surname><given-names>E</given-names></name></person-group><article-title>The role of diet in the prevention of type 2 diabetes</article-title><source>Nutr Metab Cardiovasc Dis</source><year>2011</year><volume>21 Suppl 2</volume><fpage>B32</fpage><lpage>B48</lpage><pub-id pub-id-type="pmid">21745730</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Fig.&#x000a0;1</label><caption><p>Study design. Closed circles indicate patients&#x02019; schedule of visiting hospital during control and experimental periods.</p></caption><graphic xlink:href="jcbn14-132f01"/></fig><table-wrap id="T1" position="float"><label>Table&#x000a0;1</label><caption><p>Composition of MHN-01 and standard balanced formula</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">MHN-01</th><th colspan="2" align="center" rowspan="1">Standard balanced formula (SBF)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Energy</td><td align="center" rowspan="1" colspan="1">1&#x000a0;kcal/ml</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1&#x000a0;kcal/ml</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Protein</td><td align="center" rowspan="1" colspan="1">20.0%</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">16.0%</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fat</td><td align="center" rowspan="1" colspan="1">29.7%</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">25.0%</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;SFA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">10.9%</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">24.0%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;MUFA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">72.3%</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">52.0%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;PUFA</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">15.1%</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">21.0%</td></tr><tr><td align="left" rowspan="1" colspan="1">Carbohydrate</td><td align="center" rowspan="1" colspan="1">50.3%</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">59.0%</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Branched dextrin</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">23.9%</td><td align="left" rowspan="1" colspan="1">Sucrose</td><td align="center" rowspan="1" colspan="1">3.2%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Xylitol</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">5.3%</td><td align="left" rowspan="1" colspan="1">Dextrin</td><td align="center" rowspan="1" colspan="1">92.7%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Isomaltulose</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">55.7%</td><td align="left" rowspan="1" colspan="1">Dietary fiber</td><td align="center" rowspan="1" colspan="1">4.1%</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Other carboydrate</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">15.1%</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>Other carbohydrate: mixed carbohydrate from raw material and dietary fiber.</p></table-wrap-foot></table-wrap><table-wrap id="T2" position="float"><label>Table&#x000a0;2</label><caption><p>Changes of clinical parameters by nutritional counseling</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">0 week</th><th align="center" rowspan="1" colspan="1">12 week</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N (M/F)</td><td colspan="2" align="center" rowspan="1">41 (16/25)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body weight (kg)</td><td align="center" rowspan="1" colspan="1">76.5&#x000a0;&#x000b1;&#x000a0;16.2</td><td align="center" rowspan="1" colspan="1">76.1&#x000a0;&#x000b1;&#x000a0;16.1</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">29.4&#x000a0;&#x000b1;&#x000a0;4.0</td><td align="center" rowspan="1" colspan="1">29.2&#x000a0;&#x000b1;&#x000a0;4.7</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="center" rowspan="1" colspan="1">95.4&#x000a0;&#x000b1;&#x000a0;10.4</td><td align="center" rowspan="1" colspan="1">96.5&#x000a0;&#x000b1;&#x000a0;13.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">130.4&#x000a0;&#x000b1;&#x000a0;16.8</td><td align="center" rowspan="1" colspan="1">124.3&#x000a0;&#x000b1;&#x000a0;14.8*</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">83.6&#x000a0;&#x000b1;&#x000a0;11.8</td><td align="center" rowspan="1" colspan="1">76.7&#x000a0;&#x000b1;&#x000a0;12.0*</td></tr><tr><td align="left" rowspan="1" colspan="1">Energy intake (kcal/day)</td><td align="center" rowspan="1" colspan="1">1,876&#x000a0;&#x000b1;&#x000a0;459</td><td align="center" rowspan="1" colspan="1">1,728&#x000a0;&#x000b1;&#x000a0;319*</td></tr><tr><td align="left" rowspan="1" colspan="1">FPG (mg/dl)</td><td align="center" rowspan="1" colspan="1">108&#x000a0;&#x000b1;&#x000a0;9</td><td align="center" rowspan="1" colspan="1">108&#x000a0;&#x000b1;&#x000a0;13</td></tr><tr><td align="left" rowspan="1" colspan="1">FIRI (&#x000b5;U/ml)</td><td align="center" rowspan="1" colspan="1">6.7&#x000a0;&#x000b1;&#x000a0;3.7</td><td align="center" rowspan="1" colspan="1">9.0&#x000a0;&#x000b1;&#x000a0;4.8*</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td align="center" rowspan="1" colspan="1">1.78&#x000a0;&#x000b1;&#x000a0;1.01</td><td align="center" rowspan="1" colspan="1">2.44&#x000a0;&#x000b1;&#x000a0;1.46*</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin A1c (%)</td><td align="center" rowspan="1" colspan="1">5.6&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" rowspan="1" colspan="1">5.4&#x000a0;&#x000b1;&#x000a0;0.4*</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#x000a0;&#x000b1;&#x000a0;SD. *vs 0 week (<italic>p</italic>&#x0003c;0.05). BMI, body mass index; FPG, fasting plasma glucose; FIRI, fasting immune-reactive insulin; HOMA-IR, the homeostasis model assessment for insulin resistance.</p></table-wrap-foot></table-wrap><table-wrap id="T3" position="float"><label>Table&#x000a0;3</label><caption><p>Changes of clinical parameters in the improved and the non-improved groups by nutritional counseling</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">The qualified (non-improve) group<hr/></th><th colspan="2" align="center" rowspan="1">The unqualified (improve) group<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">0 week</th><th align="center" rowspan="1" colspan="1">12 week</th><th align="center" rowspan="1" colspan="1">0 week</th><th align="center" rowspan="1" colspan="1">12 week</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N (M/F)</td><td colspan="2" align="center" rowspan="1">25 (8/17)</td><td colspan="2" align="center" rowspan="1">16 (8/8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body weight (kg)</td><td align="center" rowspan="1" colspan="1">76.0&#x000a0;&#x000b1;&#x000a0;16.5</td><td align="center" rowspan="1" colspan="1">75.7&#x000a0;&#x000b1;&#x000a0;16.6</td><td align="center" rowspan="1" colspan="1">77.3&#x000a0;&#x000b1;&#x000a0;14.8</td><td align="center" rowspan="1" colspan="1">76.6&#x000a0;&#x000b1;&#x000a0;15.5</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">29.8&#x000a0;&#x000b1;&#x000a0;5.1</td><td align="center" rowspan="1" colspan="1">29.6&#x000a0;&#x000b1;&#x000a0;5.1</td><td align="center" rowspan="1" colspan="1">28.7&#x000a0;&#x000b1;&#x000a0;3.6</td><td align="center" rowspan="1" colspan="1">28.4&#x000a0;&#x000b1;&#x000a0;4.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="center" rowspan="1" colspan="1">95.4&#x000a0;&#x000b1;&#x000a0;10.6</td><td align="center" rowspan="1" colspan="1">95.9&#x000a0;&#x000b1;&#x000a0;10.9</td><td align="center" rowspan="1" colspan="1">95.4&#x000a0;&#x000b1;&#x000a0;10.5</td><td align="center" rowspan="1" colspan="1">94.2&#x000a0;&#x000b1;&#x000a0;11.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">130.6&#x000a0;&#x000b1;&#x000a0;20.4</td><td align="center" rowspan="1" colspan="1">126.5&#x000a0;&#x000b1;&#x000a0;15.8</td><td align="center" rowspan="1" colspan="1">130.1&#x000a0;&#x000b1;&#x000a0;11.1</td><td align="center" rowspan="1" colspan="1">120.9&#x000a0;&#x000b1;&#x000a0;12.8*</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">82.&#x000a0;&#x000b1;&#x000a0;13.4</td><td align="center" rowspan="1" colspan="1">77.2&#x000a0;&#x000b1;&#x000a0;12.9*</td><td align="center" rowspan="1" colspan="1">85.7&#x000a0;&#x000b1;&#x000a0;9.3</td><td align="center" rowspan="1" colspan="1">75.9&#x000a0;&#x000b1;&#x000a0;10.7*</td></tr><tr><td align="left" rowspan="1" colspan="1">Energy intake (kcal/day)</td><td align="center" rowspan="1" colspan="1">1,776&#x000a0;&#x000b1;&#x000a0;453</td><td align="center" rowspan="1" colspan="1">1,687&#x000a0;&#x000b1;&#x000a0;309</td><td align="center" rowspan="1" colspan="1">2,174&#x000a0;&#x000b1;&#x000a0;354<sup>#</sup></td><td align="center" rowspan="1" colspan="1">1,850&#x000a0;&#x000b1;&#x000a0;340*</td></tr><tr><td align="left" rowspan="1" colspan="1">FPG (mg/dl)</td><td align="center" rowspan="1" colspan="1">109&#x000a0;&#x000b1;&#x000a0;8</td><td align="center" rowspan="1" colspan="1">109&#x000a0;&#x000b1;&#x000a0;6</td><td align="center" rowspan="1" colspan="1">106&#x000a0;&#x000b1;&#x000a0;10</td><td align="center" rowspan="1" colspan="1">107&#x000a0;&#x000b1;&#x000a0;19</td></tr><tr><td align="left" rowspan="1" colspan="1">FIRI (&#x000b5;U/ml)</td><td align="center" rowspan="1" colspan="1">5.9&#x000a0;&#x000b1;&#x000a0;2.8</td><td align="center" rowspan="1" colspan="1">8.4&#x000a0;&#x000b1;&#x000a0;3.5*</td><td align="center" rowspan="1" colspan="1">8.0&#x000a0;&#x000b1;&#x000a0;4.5</td><td align="center" rowspan="1" colspan="1">10.1&#x000a0;&#x000b1;&#x000a0;6.3</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td align="center" rowspan="1" colspan="1">1.60&#x000a0;&#x000b1;&#x000a0;0.80</td><td align="center" rowspan="1" colspan="1">2.24&#x000a0;&#x000b1;&#x000a0;0.89*</td><td align="center" rowspan="1" colspan="1">2.08&#x000a0;&#x000b1;&#x000a0;1.24</td><td align="center" rowspan="1" colspan="1">2.76&#x000a0;&#x000b1;&#x000a0;2.07</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin A1c (%)</td><td align="center" rowspan="1" colspan="1">5.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" rowspan="1" colspan="1">5.6&#x000a0;&#x000b1;&#x000a0;0.3*</td><td align="center" rowspan="1" colspan="1">5.4&#x000a0;&#x000b1;&#x000a0;0.3<sup>#</sup></td><td align="center" rowspan="1" colspan="1">5.3&#x000a0;&#x000b1;&#x000a0;0.3*<sup>,&#x02020;</sup></td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#x000a0;&#x000b1;&#x000a0;SD. *vs 0 week (<italic>p</italic>&#x0003c;0.05). <sup>#</sup>vs The qualified (non-improved) group at 0 week (<italic>p</italic>&#x0003c;0.05). <sup>&#x02020;</sup>vs The qualified (non-improved) group at 12 week (<italic>p</italic>&#x0003c;0.05). BMI, body mass index; FPG, fasting plasma glucose; FIRI, fasting immune-reactive insulin; HOMA-IR, the homeostasis model assessment for insulin resistance.</p></table-wrap-foot></table-wrap><table-wrap id="T4" position="float"><label>Table&#x000a0;4</label><caption><p>Effect of Inslow intake for 24 weeks on clinical parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th colspan="3" align="center" rowspan="1">MHN-01 group<hr/></th><th colspan="3" align="center" rowspan="1">Standard balanced formula (SBF) group<hr/></th></tr><tr><th rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">12 week</th><th align="center" rowspan="1" colspan="1">24 week</th><th align="center" rowspan="1" colspan="1">36 week</th><th align="center" rowspan="1" colspan="1">12 week</th><th align="center" rowspan="1" colspan="1">24 week</th><th align="center" rowspan="1" colspan="1">36 week</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N (M/F)</td><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">10 (2/8)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">12 (4/8)</td><td rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Body weight (kg)</td><td align="center" rowspan="1" colspan="1">74.9&#x000a0;&#x000b1;&#x000a0;21.0</td><td align="center" rowspan="1" colspan="1">74.2&#x000a0;&#x000b1;&#x000a0;20.7</td><td align="center" rowspan="1" colspan="1">74.4&#x000a0;&#x000b1;&#x000a0;21.1</td><td align="center" rowspan="1" colspan="1">74.9&#x000a0;&#x000b1;&#x000a0;14.9</td><td align="center" rowspan="1" colspan="1">74.5&#x000a0;&#x000b1;&#x000a0;15.2</td><td align="center" rowspan="1" colspan="1">74.7&#x000a0;&#x000b1;&#x000a0;15.7</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">30.9&#x000a0;&#x000b1;&#x000a0;7.4</td><td align="center" rowspan="1" colspan="1">30.7&#x000a0;&#x000b1;&#x000a0;7.3</td><td align="center" rowspan="1" colspan="1">30.7&#x000a0;&#x000b1;&#x000a0;7.6</td><td align="center" rowspan="1" colspan="1">28.8&#x000a0;&#x000b1;&#x000a0;3.0</td><td align="center" rowspan="1" colspan="1">28.7&#x000a0;&#x000b1;&#x000a0;3.1</td><td align="center" rowspan="1" colspan="1">28.7&#x000a0;&#x000b1;&#x000a0;3.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="center" rowspan="1" colspan="1">102.6&#x000a0;&#x000b1;&#x000a0;21.2</td><td align="center" rowspan="1" colspan="1">102.8&#x000a0;&#x000b1;&#x000a0;20.9</td><td align="center" rowspan="1" colspan="1">101.1&#x000a0;&#x000b1;&#x000a0;21.4</td><td align="center" rowspan="1" colspan="1">93.9&#x000a0;&#x000b1;&#x000a0;7.9</td><td align="center" rowspan="1" colspan="1">92.1&#x000a0;&#x000b1;&#x000a0;5.3</td><td align="center" rowspan="1" colspan="1">92.6&#x000a0;&#x000b1;&#x000a0;5.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">131.3&#x000a0;&#x000b1;&#x000a0;20.8</td><td align="center" rowspan="1" colspan="1">124.1&#x000a0;&#x000b1;&#x000a0;19.4</td><td align="center" rowspan="1" colspan="1">125.0&#x000a0;&#x000b1;&#x000a0;18.6</td><td align="center" rowspan="1" colspan="1">126.3&#x000a0;&#x000b1;&#x000a0;13.9</td><td align="center" rowspan="1" colspan="1">125.6&#x000a0;&#x000b1;&#x000a0;9.4</td><td align="center" rowspan="1" colspan="1">132.0&#x000a0;&#x000b1;&#x000a0;10.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic blood pressure (mmHg)</td><td align="center" rowspan="1" colspan="1">78.4&#x000a0;&#x000b1;&#x000a0;15.7</td><td align="center" rowspan="1" colspan="1">78.4&#x000a0;&#x000b1;&#x000a0;10.7</td><td align="center" rowspan="1" colspan="1">77.4&#x000a0;&#x000b1;&#x000a0;10</td><td align="center" rowspan="1" colspan="1">80.9&#x000a0;&#x000b1;&#x000a0;11.4</td><td align="center" rowspan="1" colspan="1">78.9&#x000a0;&#x000b1;&#x000a0;11.1</td><td align="center" rowspan="1" colspan="1">82.6&#x000a0;&#x000b1;&#x000a0;10.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Energy intake (kcal/day)</td><td align="center" rowspan="1" colspan="1">1,799&#x000a0;&#x000b1;&#x000a0;330</td><td align="center" rowspan="1" colspan="1">1,758&#x000a0;&#x000b1;&#x000a0;401</td><td align="center" rowspan="1" colspan="1">1,582&#x000a0;&#x000b1;&#x000a0;263</td><td align="center" rowspan="1" colspan="1">1,552&#x000a0;&#x000b1;&#x000a0;270</td><td align="center" rowspan="1" colspan="1">1,660&#x000a0;&#x000b1;&#x000a0;276</td><td align="center" rowspan="1" colspan="1">1,657&#x000a0;&#x000b1;&#x000a0;427</td></tr><tr><td align="left" rowspan="1" colspan="1">FPG (mg/dl)</td><td align="center" rowspan="1" colspan="1">108&#x000a0;&#x000b1;&#x000a0;6</td><td align="center" rowspan="1" colspan="1">109&#x000a0;&#x000b1;&#x000a0;10</td><td align="center" rowspan="1" colspan="1">107&#x000a0;&#x000b1;&#x000a0;6</td><td align="center" rowspan="1" colspan="1">110&#x000a0;&#x000b1;&#x000a0;270</td><td align="center" rowspan="1" colspan="1">111&#x000a0;&#x000b1;&#x000a0;10</td><td align="center" rowspan="1" colspan="1">112&#x000a0;&#x000b1;&#x000a0;12</td></tr><tr><td align="left" rowspan="1" colspan="1">FIRI (&#x000b5;U/ml)</td><td align="center" rowspan="1" colspan="1">9.3&#x000a0;&#x000b1;&#x000a0;4.1</td><td align="center" rowspan="1" colspan="1">8.0&#x000a0;&#x000b1;&#x000a0;2.7</td><td align="center" rowspan="1" colspan="1">7.9&#x000a0;&#x000b1;&#x000a0;2.4</td><td align="center" rowspan="1" colspan="1">8.2&#x000a0;&#x000b1;&#x000a0;2.9</td><td align="center" rowspan="1" colspan="1">9.0&#x000a0;&#x000b1;&#x000a0;3.7</td><td align="center" rowspan="1" colspan="1">8.1&#x000a0;&#x000b1;&#x000a0;2.9</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td align="center" rowspan="1" colspan="1">2.47&#x000a0;&#x000b1;&#x000a0;1.03</td><td align="center" rowspan="1" colspan="1">2.14&#x000a0;&#x000b1;&#x000a0;0.67</td><td align="center" rowspan="1" colspan="1">2.08&#x000a0;&#x000b1;&#x000a0;0.65</td><td align="center" rowspan="1" colspan="1">2.23&#x000a0;&#x000b1;&#x000a0;0.75</td><td align="center" rowspan="1" colspan="1">2.40&#x000a0;&#x000b1;&#x000a0;0.83</td><td align="center" rowspan="1" colspan="1">2.26&#x000a0;&#x000b1;&#x000a0;0.86</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin A1c (%)</td><td align="center" rowspan="1" colspan="1">5.6&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="center" rowspan="1" colspan="1">5.6&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" rowspan="1" colspan="1">5.6&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" rowspan="1" colspan="1">5.6&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" rowspan="1" colspan="1">5.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="center" rowspan="1" colspan="1">5.7&#x000a0;&#x000b1;&#x000a0;0.4*</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal visceral fat (cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">144.1&#x000a0;&#x000b1;&#x000a0;81.8</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">146.0&#x000a0;&#x000b1;&#x000a0;77.2</td><td align="center" rowspan="1" colspan="1">137.7&#x000a0;&#x000b1;&#x000a0;39.6</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">135.2&#x000a0;&#x000b1;&#x000a0;38.1</td></tr><tr><td align="left" rowspan="1" colspan="1">OGTT AUCpg (mg&#x000b7;h/dl)</td><td align="center" rowspan="1" colspan="1">350.5&#x000a0;&#x000b1;&#x000a0;40.0</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">361.9&#x000a0;&#x000b1;&#x000a0;50.2</td><td align="center" rowspan="1" colspan="1">346.6&#x000a0;&#x000b1;&#x000a0;51.7</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">365.6&#x000a0;&#x000b1;&#x000a0;56.5</td></tr><tr><td align="left" rowspan="1" colspan="1">OGTT AUCiri (&#x000b5;U&#x000b7;h/ml)</td><td align="center" rowspan="1" colspan="1">79.9&#x000a0;&#x000b1;&#x000a0;37.6</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">66.0&#x000a0;&#x000b1;&#x000a0;35.1</td><td align="center" rowspan="1" colspan="1">80.7&#x000a0;&#x000b1;&#x000a0;45.3</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">64.2&#x000a0;&#x000b1;&#x000a0;31.9</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean&#x000a0;&#x000b1;&#x000a0;SD. *vs SBF group at 12 week (<italic>p</italic>&#x0003c;0.05). BMI, body mass index; FPG, fasting plasma glucose; FIRI, fasting immune-reactive insulin; HOMA-IR, the homeostasis model assessment for insulin resistance.</p></table-wrap-foot></table-wrap></floats-group></article>